Research programme: PPAR pan-agonists for obesity - Plexxikon
Alternative Names: Nuclear receptor therapeutic for obesity - PlexxikonLatest Information Update: 07 Jul 2022
At a glance
- Originator Plexxikon
- Class Small molecules
- Mechanism of Action Peroxisome proliferator-activated receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 06 Jul 2022 Discontinued - Preclinical for Obesity in USA (unspecified route)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Obesity in USA
- 04 Apr 2011 Plexxikon has been acquired by Daiichi Sankyo Company